Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
UBS
Baxter
Dow
Covington
Fish and Richardson
QuintilesIMS
Federal Trade Commission
Healthtrust
Novartis

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021303

« Back to Dashboard
NDA 021303 describes ADDERALL XR 5, which is a drug marketed by Shire and is included in one NDA. It is available from seven suppliers. There are four patents protecting this drug. Additional details are available on the ADDERALL XR 5 profile page.

The generic ingredient in ADDERALL XR 5 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-three drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for NDA: 021303

Tradename:
6
Applicant:
1
Ingredient:
1
Patents:4
Formulation / Manufacturing:see details

Pharmacology for NDA: 021303

Suppliers and Packaging for NDA: 021303

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADDERALL XR 10
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL 021303 NDA AUTHORIZED GENERIC Global Pharmaceuticals, Division of Impax Laboratories Inc. 0115-1328 0115-1328-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1328-01)
ADDERALL XR 10
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL 021303 NDA AUTHORIZED GENERIC Global Pharmaceuticals, Division of Impax Laboratories Inc. 0115-1329 0115-1329-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0115-1329-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength2.5MG;2.5MG;2.5MG;2.5MG
Approval Date:Oct 11, 2001TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Apr 21, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Apr 21, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Apr 21, 2019Product Flag?Substance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Citi
Queensland Health
AstraZeneca
Fish and Richardson
Covington
McKesson
UBS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot